Treatment expands options for HER2-negative metastatic breast cancer

New methodology may boost innovation in protein engineering

CSL Behring’s study reveals significant long-term benefits

Partnership aims to leverage cutting-edge technology in clinical trials

Designation follows promising preclinical data and FDA clearance

Breast cancer therapy offers hope for patients at risk of recurrence

Partnership aims to create recombinant nanobodies to treat immune disorders

Study shows AP-325 offers lasting pain relief without central side effects

Funding led by new investors FSG and EIC Fund

Positive opinion issued for marketing authorisation extension